8NE:FRA
Lisata Therapeutics, Inc.
0,82 €
arrow_downward
-0,61%(-0,0050) 1K
13-okt, 11:46:17 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto8NE tikeri uchun statistika yaratilmoqda...
Ochish
0,82 €
Yuqori
0,82 €
Past
0,82 €
Bozor kapitali
11,29 mln
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
4,34 €
52 haftalik eng past
0,74 €
Xodimlar soni
21
Ochish
0,82 €
Yuqori
0,82 €
Past
0,82 €
Bozor kapitali
11,29 mln
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
4,34 €
52 haftalik eng past
0,74 €
Xodimlar soni
21
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Simply Wall Street
·
17 daqiqa oldin
Marvell Technology (MRVL) Introduced First Six Channel CXL 3.2 Memory Expanders
Benzinga
·
1 soat oldin
VERAXA Biotech (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at Worl
Stock Titan
·
1 soat oldin
Nasdaq files to remove Bone Biologics (Nasdaq: BBLG) warrants from listing and/or registration.
Yahoo Finance
·
51 daqiqa oldin
XRP Fell 8% in the Week It Got a Nasdaq Listing, a Dubai Bank Deal and an ETF Inflow. Why Did None of It Count?
Profil
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Lisata Therapeutics, Inc. haqida
CEO-
Xodimlar soni21
Asos solingan1980
Bosh ofislarBasking Ridge, N'yu-Jersi, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytlisata.com